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Abstract
Background: Aberrant accumulation of β-catenin plays an important role in a variety of human
neoplasms. We recently reported accumulation of β-catenin in parathyroid adenomas from
patients with primary hyperparathyroidism (pHPT). In CTNNB1 exon 3, we detected a stabilizing
mutation (S37A) in 3 out of 20 analyzed adenomas. The aim of the present study was to determine
the frequency and zygosity of mutations in CTNNB1 exon 3, and β-catenin accumulation in a large
series of parathyroid adenomas of Swedish patients.
Results: The mutation S37A (TCT > GCT) was detected by direct DNA sequencing of PCR
fragments in 6 out of 104 sporadic parathyroid adenomas (5.8%). Taking our previous study into
account, a total of 9 out of 124 (7.3%) adenomas displayed the same mutation. The mutations were
homozygous by DNA sequencing, restriction enzyme cleavage, and gene copy number
determination using the GeneChip 500 K Mapping Array Set. All tumors analyzed by
immunohistochemistry, including those with mutation, displayed aberrant β-catenin accumulation.
Western blotting revealed a slightly higher expression level of β-catenin and nonphosphorylated
active β-catenin in tumors with mutation compared to those without. Presence of the mutation
was not related to distinct clinical characteristics.
Conclusion: Aberrant accumulation of β-catenin is very common in parathyroid tumors, and is
caused by stabilizing homozygous mutation in 7.3% of Swedish pHPT patients.
Background
Parathyroid disease with hypersecretion of parathyroid
hormone and generally also hypercalcemia occurs in pri-
mary hyperparathyroidism (pHPT), due to growth regula-
tory disturbance in one or several parathyroid glands.
Activation of CCND1 oncogene expression or inactivation
of the MEN1 tumor suppressor gene contributes to dereg-
ulated growth control in a fraction of sporadic parathy-
roid adenomas [1-4].
Activation of the Wnt/β-catenin signaling pathway by
aberrant accumulation of stabilized β-catenin is involved
in the development of many neoplasms. β-catenin accu-
mulation is typically caused by mutations in components
of the signaling pathway, such as APC, Axin, β-Trcp, and
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WTX, or results from secondary events. In addition, pro-
tein stabilizing mutations in the glycogen synthase kinase
3β phosphorylation sites of β-catenin (Ser-33, Ser-37, Thr-
41, Ser-45) occur with varying frequency in several neo-
plasms [5-9].
We recently reported activation of the Wnt/β-catenin sig-
naling pathway by aberrant accumulation of β-catenin in
parathyroid adenomas from patients with pHPT [10]. The
accumulation of β-catenin was caused by expression of an
aberrantly spliced internally truncated Wnt receptor LRP5
or by a stabilizing mutation (S37A) in CTNNB1 exon 3
[10,11]. Stabilizing mutations of CTNNB1 have not been
detected in parathyroid adenomas of patients from Japan
and the United States [12,13]. Here we have determined
the frequency and zygosity of mutations in exon 3 of
CTNNB1, and β-catenin expression status in a large series
of parathyroid adenomas of Swedish patients.
Methods
Tissue Specimens
Sporadic parathyroid adenomas (n = 104) were acquired
from 104 Swedish patients with pHPT diagnosed and
operated on in the clinical routine at the Uppsala Univer-
sity Hospital. Normal parathyroid tissue was obtained as
normal gland biopsies in patients subjected to parathy-
roidectomy. Tissues were intraoperatively snap frozen.
Informed consent and approval of institutional ethical
committee were obtained.
DNA Sequencing
DNA from parathyroid tumors was prepared by standard
procedures including proteinase K treatment and phenol
extraction. Blood DNA was prepared using the Wizard
Genomic DNA Purification Kit (Promega Corp., Madison,
WI). DNA was PCR amplified with primers for exon 3 of
CTNNB1. PCR forward primer: 5'-TGA TGG AGT TGG
ACA TGG CC; reverse: 5'-CTC ATA CAG GAC TTG GGA
GG. The complementary strand was also sequenced for
fragments with mutation. The PCR fragments were
sequenced directly on the 3130xl Genetic Analyzer using
the ABI Prism Dye Terminator Cycle Sequencing Ready
Reaction kit (Applied Biosystems, Foster City, CA).
Restriction Enzyme Digestion
CTNNB1 exon 3 PCR fragments were purified using the
GFX PCR DNA and Gel Band Purification Kit (GE Health-
care Europe GmbH, Uppsala, Sweden) and cleaved with
Xma I or Nla III according to instructions by the manufac-
turer (New England Biolabs, Inc., Beverly, MA). Products
were analyzed by agarose gel electrophoresis.
CTNNB1 Gene Copy Number
Tumor (S37A) and blood DNA from 4 patients were
extracted as described above. DNA was marked with fluo-
rescence dye and hybridized to the Affymetrix GeneChip
Mapping 500 K Set Arrays 250K_Nsp_SNP and
250K_Sty_SNP according to the manufacturer's instruc-
tions, and analysed by GeneChip Genotyping Analysis
Software (GTYPE) using Chromosome Copy Number
Analysis Tool (CNAT) (Affymetrix, Inc. Santa Clara, Cali-
fornia, USA). Informative SNPs used in the gene copy
number determination are shown in Table 1. The experi-
ment was performed at the Bioinformatics and Expression
Analysis core facility at NOVUM, Karolinska Institute,
Huddinge, Sweden.
Immunohistochemistry and Western Blotting
Frozen tissue sections were stained as described [10] using
an anti-β-catenin goat polyclonal antibody with an
epitope mapping at the C-terminus (Santa Cruz Biotech-
nology, INC., Santa Cruz, CA; catalog no. sc-1496). Pro-
tein extracts for Western blotting were prepared [10] in
Cytobuster Protein Extract Reagent (Novagen Inc., Madi-
son, Wisconsin, USA) supplemented with Complete pro-
tease inhibitor cocktail (Roche Diagnostics GmbH,
Penzberg, Germany). The anti-active (nonphosphor-
ylated)  β-catenin [14] mouse monoclonal antibody
(Upstate, Lake Placid, USA, # 05-665), the anti-β-catenin
goat polyclonal antibody (above), and anti-actin goat pol-
yclonal antibody (Santa Cruz Biotechnology INC.) were
used. After incubation with the appropriate secondary
Table 1: SNP genotyping
SNP position refSNP ID Patient 1 Patient 2 Patient 3 Patient 4
41205658 rs7630377 ECN ECN ECN ECN
41209520 rs9859392 ECN ECN ECN ECN
41218746 rs3915129 ECN NI ECN ECN
41237448 rs13072632 ECN ECN ECN ECN
41243358 rs11564447 ECN ECN NI ECN
41262697 rs9824212 ECN ECN ECN ECN
41268711 rs1880480 ECN ECN ECN ECN
Constitutional DNA and parathyroid adenoma DNA with CTNNB1 mutation S37A from 4 pHPT patients were genotyped with the GeneChip 500 
K Mapping Array Set. The CTNNB1 gene is located between positions 41216016 and 41256928 http://genome.ucsc.edu. ECN, equal copy number. 
NI, non-informative.Molecular Cancer 2008, 7:53 http://www.molecular-cancer.com/content/7/1/53
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antibodies, bands were visualized using the enhanced
chemiluminescence system (GE Healthcare Europe
GmbH, Uppsala, Sweden). Membranes were scanned by
the ChemiDoc XRS and the band intensities were deter-
mined using Quantity One Software (Bio-Rad Laborato-
ries, Inc., Hercules, California, USA).
Statistical Analyses
Unpaired t test, z test, and χ2 test were used. The data were
calculated with Statistica 6 (StatSoft, Tulsa, OK, USA). Val-
ues are presented as arithmetrical mean ± SEM.
Results
Homozygous CTNNB1 Stabilizing Mutation S37A
DNA sequencing analysis detected the CTNNB1 stabiliz-
ing mutation S37A (TCT > GCT) in 6 out of the 104
(5.8%) analyzed parathyroid adenomas (Figure 1). Con-
stitutional DNA (blood) from 4 out of the 6 patients were
available, and encoded the wild-type CTNNB1 sequence.
The mutations were apparently homozygous by DNA
sequencing (Figure 1), as we reported previously for 3 out
of 20 adenomas [10]. Taking our previous study into
account [10], a total of 9 out of 124 (7.3%) randomly
selected parathyroid adenomas displayed the CTNNB1
stabilizing mutation S37A.
Homozygosity for the mutation was further substantiated
by analytical restriction enzyme digestions. As expected,
all 9 fragments harbouring S37A were completely cleaved
by Nla III and not by Xma I (Figure 2A). Vice versa was
observed for fragments with the wild-type codon S37.
PCR amplified fragments were used for the DNA sequenc-
ing and restriction analyses, and PCR reactions could in
theory favour the mutant allele(s). Unbiased PCR reac-
tions were however confirmed by performing PCR ampli-
fication in a 1:1 mixture of constitutional DNA and S37A
mutant tumor DNA, and by subsequent analytical restric-
tion enzyme digestion (Figure 2B).
In order to resolve the issue of zygosity for the S37A muta-
tion, 4 tumor DNAs with the corresponding constitu-
tional DNAs were genotyped with the GeneChip 500 K
Mapping Array Set (Affymetrix). Gene copy number anal-
ysis was done by comparison of informative single-nucle-
otide polymorphisms (SNPs). Five informative SNPs in
CTNNB1 and 2 SNPs downstream of the gene showed
equal copy number for the 4 paired DNA samples (Table
1). Thus, taking also the DNA sequencing results into
account the S37A mutation was homozygous in these 4
tumours, rather than hemizygous with one mutant and
one deleted CTNNB1 allele.
Representative results of direct DNA sequencing of CTNNB1 exon 3 Figure 1
Representative results of direct DNA sequencing of CTNNB1 exon 3. Constitutional DNA from blood (left panel) and 
parathyroid adenoma (right panel) of the same pHPT patient.
Ala 37 Ser 37
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Analytical restriction enzyme cleavage analysis Figure 2
Analytical restriction enzyme cleavage analysis. (A), CTNNB1 exon 3 PCR fragments (176 bp) were digested with Xmn 
I or Nla III that cuts only wild-type or only S37A mutant sequences, respectively. Three out of the nine parathyroid adenomas 
with S37A mutation were identified in our previous study [10]. Nla III cuts also outside of codon 37, close to the fragment end 
(23 bp). U; uncleaved CTNNB1 exon 3 PCR fragment. (B), CTNNB1 exon 3 was PCR amplified from a 1:1 mixture of constitu-
tional DNA and tumor DNA with the S37A mutation. The fragment was analyzed by restriction enzyme digestions as in (A).
B
GGA ATC CAT TCT GGT
GGA ATC CAT GCT GGT
   GA ANN NNT TC
             CAT G
S37
Wt
S37A mutant
Xmn I cuts only wt
Nla III cuts only mutant
Restriction endonuclease
               sites
ESĺ Adenomas with
 S37A mutation ESĺ
Adenomas with 
      S37 (Wt)
Xmn I      -    -    +    -     +    -     +     -    +     -    +    -    +    -    +    -    +     -     +
Nla III      -    +    -    +     -    +     -    +    -     +    -    +    -    +     -    +    -     +     -
A
 U       1           2          3          4          5          6          7           8           9
ESĺ
Xmn I      -              -              +                -              +              -               +         
Nla III      -                +              -                +              -              +               -    
Constitutional DNA               Tumor DNA (S37A)       Constitutional DNA
                                                                                                      +
                                                                                        Tumor DNA(S37A)
                          1:1
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β-catenin Protein Expression
Previously, we reported aberrant accumulation of β-cat-
enin in all (n = 37) analyzed parathyroid adenomas [10].
Of the tumors analyzed here by DNA sequencing, 81 fro-
zen parathyroid adenomas, including 6 with the S37A
mutation, were of sufficient good quality for immunohis-
tochemical analysis with a β-catenin goat polyclonal pep-
tide antiserum [10]. The three pHPT tumors with S37A
mutation described previously [10] were also included. In
addition to membraneous staining, all 84 tumors dis-
played distinct cytoplasmic/nuclear immunoreactivity
(Figure 3). Western blotting analysis was performed to
compare the expression level of β-catenin as well as of
nonphosphorylated active β-catenin (ratio of β-catenin to
actin) in tumors with (n = 8) and without (n = 6) the sta-
bilizing mutation S37A (Figure 4). The six tumors without
β-catenin stabilizing mutation all expressed the internally
truncated LRP5 receptor [11], and as expected [10,11] all
fourteen tumors showed accumulation of nonphosphor-
ylated active β-catenin in comparison to normal parathy-
roid tissue (not shown). A small but significantly higher
expression level was observed of both β-catenin and non-
phosphorylated active β-catenin in tumors with stabiliz-
ing mutation S37A in comparison to those with wild type
β-catenin. The ratio of nonphosphorylated active β-cat-
enin to β-catenin was also slightly higher in tumors with
β-catenin stabilizing mutation (Figure 4). No particular
clinical characteristics, including age, sex, serum calcium
level, serum PTH level or gland weight related to presence
of the S37A mutation.
Discussion
We have found that a total of 9 out of 124 (7.3%) ran-
domly selected parathyroid adenomas displayed the
CTNNB1 stabilizing homozygous mutation S37A. None
of these 9 tumors expressed the internally truncated LRP5
receptor [11] (data not shown), further emphasizing the
previous observation that these events are mutually exclu-
sive [11]. The mutated LRP5 receptor, with the central
region deleted, is expressed in the majority of pHPT
tumors and is required for accumulation of β-catenin and
parathyroid tumor cell growth [11].
The S37A CTNNB1 mutation commonly occurs also in
gastrointestinal carcinoid tumors where 26 out of 29
tumors with mutations harboured S37A [15]. The mutant
protein shows resistance to ubiquination and proteo-
somal degradation, with a longer half-life than wild-type
β-catenin. S37A β-catenin also shows an enhanced affinity
for LEF1 and TCF4, its DNA-binding partners in transcrip-
tional regulation [16-18]. Homozygous mutation as
detected by direct DNA sequencing of CTNNB1 seems to
be uncommon in other neoplasms, but have been
described in a rectal carcinoid tumor and in colorectal
cancer [15,19]. To be conclusive regarding zygosity, direct
DNA sequencing clearly requires low or no contamina-
tion of normal cell populations in the tumor sample. In
colorectal cancer cells with inactivating APC hemizygous
mutation or activating CTNNB1 heterozygous mutation,
the total β-catenin signaling activity seemed dependent
also on silencing of SFRP genes by promoter hypermeth-
ylation with consistent constitutive WNT signaling [20].
Whether combined activity of two mutant S37A CTNNB1
alleles suffices for benign parathyroid tumor growth or
whether constitutive WNT signaling is required in addi-
tion, remain to be investigated.
DNA sequence analysis of 24 parathyroid adenomas from
Japanese patients revealed no CTNNB1 mutations, and
immunohistochemistry showed weak cytoplasmic β-cat-
enin staining in 2 tumors [12]. In another study from
Japan (n = 9), cytoplasmic and/or membranous β-catenin
staining was seen in 8 adenomas and nuclear staining in
one adenoma. DNA sequencing analysis was not done in
these specimens [21]. Furthermore, a recent study did not
detect CTNNB1 exon 3 mutations in 97 sporadic parathy-
roid adenomas from patients who had undergone parath-
yroidectomy in the United States. Unfortunately, β-
catenin protein expression was not evaluated in this
report [13]. Since we observed a CTNNB1 mutation fre-
quency of 7.3% in adenomas from Swedish patients, this
may suggest possible contribution of geographical origin
(dietary or environmental differences, or different genetic
backgrounds) to mechanisms of parathyroid disease. The
CTNNB1 mutation frequency vary considerably also in
colorectal cancer (1–60%) and melanomas (0.02–27%),
apparently not related to geographical origin [8,17,22-
30]. The observations may be attributed to the stochastic
distribution of probability in analyzed material or to
other causalities, like that the tumor sample purity and
pathology must be guaranteed.
Conclusion
By analyzing a large series of tumors from Swedish
patients, this study further emphasizes β-catenin accumu-
lation as the most common aberration in parathyroid
tumors of primary origin. CTNNB1-stabilizing mutations
were found in 5.8% of the tumors, or in 7.3% when taking
our previous study [10] into account. The WNT/β-catenin
signaling pathway, with β-catenin and the internally trun-
cated LRP5 receptor [11] in particular, present therapeutic
targets for hyperparathyroidism.
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Immunohistochemical analysis of β-catenin Figure 3
Immunohistochemical analysis of β-catenin. Immunostaining of 84 parathyroid adenomas with an anti-β-catenin goat pol-
yclonal antibody. The first 9 tumor specimens, of which 3 were described previously [10], displayed CTNNB1 homozygous sta-
bilizing mutation S37A. No staining was seen in the absence of primary antibodies (last 4 specimens).Molecular Cancer 2008, 7:53 http://www.molecular-cancer.com/content/7/1/53
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Western blotting analysis of total and non-phosphorylated active β-catenin Figure 4
Western blotting analysis of total and non-phosphorylated active β-catenin. Eight pHPT tumors with CTNNB1 muta-
tion S37A and six pHPT tumors without mutation were analyzed. The group of six tumors expressed the internally truncated 
LRP5 receptor [11]. All analyzed tumors showed accumulation of active β-catenin in comparison to normal parathyroid tissue 
(not shown). An anti-active (nonphosphorylated) β-catenin monoclonal antibody [14] and a goat polyclonal antibody with an 
epitope mapping at the C-terminus of β-catenin were used. Quantisation of the obtained signals are shown below. *, p < 0.05.
anti-active-ß-catenin
anti-ß-catenin 
anti-actin
* *
*
A
c
t
i
v
e
-
ß
-
c
a
t
e
n
i
n
 
/
 
a
c
t
i
n
ß
-
c
a
t
e
n
i
n
 
/
 
a
c
t
i
n
A
c
t
i
v
e
-
ß
-
c
a
t
e
n
i
n
 
/
 
ß
-
c
a
t
e
n
i
n
0.1
0.2
0.3
0.4
0.5
0.6
0.5
1.0
1.5
2.0
0.5
1.0
1.5
2.0
2.5
3.0
WT S37A S37A S37A WT WT
1.47 ± 0.31  1.05 ± 0.03  1.06 ± 0.28 0.42 ± 0.07  2.14 ± 0.36  0.29 ± 0.08 
WT S37A
anti-active-ß-catenin
anti-ß-catenin 
anti-actin
WT S37APublish with BioMed Central    and   every 
scientist can read your work free of charge
"BioMed Central will be the most significant development for 
disseminating the results of biomedical research in our lifetime."
Sir Paul Nurse, Cancer Research UK
Your research papers will be:
available free of charge to the entire biomedical community
peer reviewed and published  immediately upon acceptance
cited in PubMed and archived on PubMed Central 
yours — you keep the copyright
Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp
BioMedcentral
Molecular Cancer 2008, 7:53 http://www.molecular-cancer.com/content/7/1/53
Page 8 of 8
(page number not for citation purposes)
manuscript, GW conceived of the study, participated in its
design and coordination and drafted the manuscript. All
authors read and approved the final manuscript.
Acknowledgements
This work was supported by the Swedish Research Council and Swedish 
Cancer Society. We thank the referee of another paper for suggesting the 
use of Xma I and Nla III. We are grateful to Birgitta Bondeson and Peter 
Lillhager for skilful technical assistance. We are also grateful to Marika Rön-
nholm at the Bioinformatics and Expression Analysis core facility at 
NOVUM, Karolinska Institute, Huddinge, Sweden.
References
1. Marx S: Hyperparathyroid and hypoparathyroid disorders.  N
Engl J Med 2000, 343:1863-1875.
2. Arnold A, Shattuck TM, Mallya SM, Krebs LJ, Costa J, Gallagher J, Wild
Y, Saucier K: Molecular pathogenesis of primary hyperparath-
yroidism.  J Bone Miner Res 2002, 17(Suppl 2):N30-36.
3. Åkerström G, Hellman P: Primary hyperparathyroidism.  Curr
Opin Oncol 2004, 16:1-7.
4. Åkerström G, Hellman P, Hessman O, Segersten U, Westin G: Par-
athyroid glands in calcium regulation and human disease.
Ann N Y Acad Sci 2005, 1040:53-58.
5. Polakis P: The oncogenic activation of β-catenin.  Curr Opin
Genet Dev 1999, 9:15-21.
6. Lustig B, Behrens J: The Wnt signaling pathway and its role in
tumor development.  J Cancer Res Clin Oncol 2003, 129:199-221.
7. Giles RH, van Es JH, Clevers H: Caught up in a Wnt storm: Wnt
signaling in cancer.  Biochim Biophys Acta 2003, 1653:1-24.
8. Polakis P: The many ways of Wnt in cancer.  Curr Opin Genet Dev
2007, 17:45-51.
9. Major MB, Camp ND, Berndt JD, Yi X, Goldenberg SJ, Hubbert C,
Biechele TL, Gingras AC, Zheng N, Maccoss MJ, Angers S, Moon RT:
Wilms tumor suppressor WTX negatively regulates WNT/
β-catenin signaling.  Science 2007, 316:1043-1046.
10. Björklund P, Åkerström G, Westin G: Accumulation of nonphos-
phorylated β-catenin and c-myc in primary and uremic sec-
ondary hyperparathyroid tumors.  J Clin Endocrinol Metab 2007,
92:338-344.
11. Björklund P, Åkerström G, Westin G: An LRP5 receptor with
internal deletion in hyperparathyroid tumors with implica-
tions for deregulated WNT/β-catenin signaling.  PLoS Med
2007, 4(11):e328.
12. Ikeda S, Ishizaki Y, Shimizu Y, Fujimori M, Ojima Y, Okajima M, Sugino
K, Asahara T: Immunohistochemistry of cyclin D1 and β-cat-
enin, and mutational analysis of exon 3 of β-catenin gene in
parathyroid tumors.  Int J Oncol 2002, 20:463-466.
13. Costa-Guda J, Arnold A: Absence of stabilizing mutations of β-
catenin encoded by CTNNB1 exon 3 in a large series of spo-
radic parathyroid adenomas.  J Clin Endocrinol Metab 2007,
92:1564-1566.
14. van Noort M, Meeldijk J, Zee R van der, Destree O, Clevers H: Wnt
signaling controls the phosphorylation status of beta-cat-
enin.  J Biol Chem 2002, 277:17901-17905.
15. Fujimori M, Ikeda S, Shimizu Y, Okajima M, Asahara T: Accumula-
tion of β-catenin protein and mutations in exon 3 of β-cat-
enin gene in gastrointestinal carcinoid tumor.  Cancer Res
2001, 61:6656-6659.
16. Orford K, Crockett C, Jensen JP, Weissman AM, Byers SW: Serine
phosphorylation-regulated ubiquitination and degradation
of β-catenin.  J Biol Chem 1997, 272:24735-24738.
17. Rubinfeld B, Robbins P, El-Gamil M, Albert I, Porfiri E, Polakis P: Sta-
bilization of β-catenin by genetic defects in melanoma cell
lines.  Science 1997, 275:1790-1792.
18. Williams BO, Barish GD, Klymkowsky MW, Varmus HE: A compar-
ative evaluation of β-catenin and plakoglobin signaling activ-
ity.  Oncogene 2000, 19:5720-5728.
19. Ilyas M, Tomlinson IPM, Rowan A, Pignatelli M, Bodmer WF: β-Cat-
enin mutations in cell lines established from human colorec-
tal cancers.  Proc Natl Acad Sci USA 1997, 94:10330-10334.
20. Suzuki H, Watkins DN, Jair KW, Schuebel KE, Markowitz SD, Chen
WD, Pretlow TP, Yang B, Akiyama Y, Van Engeland M, Toyota M,
Tokino T, Hinoda Y, Imai K, Herman JG, Baylin SB: Epigenetic inac-
tivation of SFRP genes allows constitutive WNT signaling in
colorectal cancer.  Nat Genet 2004, 36:417-422.
21. Semba S, Kusumi R, Moriya T, Sasano H: Nuclear accumulation of
β-catenin in human endocrine tumors: Association with Ki-
67 (MIB-1) proliferative activity.  Endocr Pathol 2000, 11:243-250.
22. Morin PJ, Sparks AB, Korinek V, Barker N, Clevers H, Vogelstein B,
Kinzler KW: Activation of beta-catenin-Tcf signaling in colon
cancer by mutations in beta-catenin or APC.  Science 1997,
275:1787-1790.
23. Sparks AB, Morin PJ, Vogelstein B, Kinzler KW: Mutational analysis
of the APC/beta-catenin/Tcf pathway in colorectal cancer.
Cancer Res 1998, 58:1130-1134.
24. Omholt K, Platz A, Ringborg U, Hansson J: Cytoplasmic and
nuclear accumulation of beta-catenin is rarely caused by
CTNNB1 exon 3 mutations in cutaneous malignant
melanoma.  Int J Cancer 2001, 92:839-842.
25. Reifenberger J, Knobbe CB, Wolter M, Blaschke B, Schulte KW, Pie-
tsch T, Ruzicka T, Reifenberger G: Molecular genetic analysis of
malignant melanomas for aberrations of the WNT signaling
pathway genes CTNNB1, APC, ICAT and BTRC.  Int J Cancer
2002, 100:549-556.
26. Pollock PM, Hayward N: Mutations in exon 3 of the beta-catenin
gene are rare in melanoma cell lines.  Melanoma Res 2002,
12:183-186.
27. Demunter A, Libbrecht L, Degreef H, De Wolf-Peeters C, Oord JJ
van den: Loss of membranous expression of beta-catenin is
associated with tumor progression in cutaneous melanoma
and rarely caused by exon 3 mutations.  Mod Pathol 2002,
15:454-461.
28. Johnson V, Volikos E, Halford SE, Eftekhar Sadat ET, Popat S, Talbot
I, Truninger K, Martin J, Jass J, Houlston R, Atkin W, Tomlinson IPM,
Silver ARJ: Exon 3 beta-catenin mutations are specifically
associated with colorectal carcinomas in hereditary non-
polyposis colorectal cancer syndrome.  Gut 2005, 54:264-267.
29. Luchtenborg M, Weijenberg MP, Wark PA, Saritas AM, Roemen GM,
van Muijen GN, de Bruine AP, Brandt PA van den, de Goeij AF: Muta-
tions in APC, CTNNB1 and K-ras genes and expression of
hMLH1 in sporadic colorectal carcinomas from the Nether-
lands Cohort Study.  BMC Cancer 2005, 5:160.
30. Thorstensen L, Lind GE, Lovig T, Diep CB, Meling GI, Rognum TO,
Lothe RA: Genetic and epigenetic changes of components
affecting the WNT pathway in colorectal carcinomas strati-
fied by microsatellite instability.  Neoplasia 2005, 7:99-108.